[go: up one dir, main page]

PE20091732A1 - Dihidropirazolonas sustituidas y su uso - Google Patents

Dihidropirazolonas sustituidas y su uso

Info

Publication number
PE20091732A1
PE20091732A1 PE2009000514A PE2009000514A PE20091732A1 PE 20091732 A1 PE20091732 A1 PE 20091732A1 PE 2009000514 A PE2009000514 A PE 2009000514A PE 2009000514 A PE2009000514 A PE 2009000514A PE 20091732 A1 PE20091732 A1 PE 20091732A1
Authority
PE
Peru
Prior art keywords
cyclobutylpiperazin
pyrimidin
compounds
dihidro
pirazol
Prior art date
Application number
PE2009000514A
Other languages
English (en)
Inventor
Mario Jeske
Ingo Flamme
Friederike Stoll
Hartmut Beck
Metin Akbaba
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40673347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091732A1 publication Critical patent/PE20091732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE DIHIDROPIRAZOLONA DE FORMULA (I) DONDE X ES N O CH; R1 ES H O CN; R2 ES HETEROCICLILO DE 4 A 7 MIEMBROS QUE ESTA UNIDO A TRAVES DE UN ATOMO DE N OPCIONALMENTE SUSTITUIDO CON HIDROXILO, HIDROXICARBONILO, ALQUILO(C1-C3), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[6-(4-CICLOBUTILPIPERAZIN-1-IL)PIRIMIDIN-4-IL]-4-(1H-IMIDAZOL-1-IL)-1,2-DIHIDRO-3H-PIRAZOL-3-ONA, 2-[6-(4-CICLOBUTILPIPERAZIN-1-IL)PIRIMIDIN-4-IL]-4-(1H-1,2,3-TRIAZOL-1-IL)-1,2-DIHIDRO-3H-PIRAZOL-3-ONA, 1-{2-[6-(4-CICLOBUTILPIPERAZIN-1-IL)PIRIMIDIN-4-IL]-3-OXO-2,3-DIHIDRO-1H-PIRAZOL-4-IL}-1H-IMIDAZOL-4-CARBONITRILO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE HIF PROLIL-4-HIDROXILASAS SIENDO UTILES EN EL TRATAMIENTO DE INSUFICIENCIA CARDIACA, ANEMIA, ANGINA DE PECHO, INFARTO DE MIOCARDIO
PE2009000514A 2008-04-23 2009-04-14 Dihidropirazolonas sustituidas y su uso PE20091732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008020113A DE102008020113A1 (de) 2008-04-23 2008-04-23 Substituierte Dihydropyrazolone und ihre Verwendung

Publications (1)

Publication Number Publication Date
PE20091732A1 true PE20091732A1 (es) 2009-12-05

Family

ID=40673347

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000514A PE20091732A1 (es) 2008-04-23 2009-04-14 Dihidropirazolonas sustituidas y su uso

Country Status (29)

Country Link
US (3) US8067407B2 (es)
EP (1) EP2265602B1 (es)
JP (1) JP5579165B2 (es)
KR (1) KR20100135838A (es)
CN (1) CN102015685B (es)
AR (1) AR071376A1 (es)
AU (1) AU2009240311B2 (es)
BR (1) BRPI0911594A2 (es)
CA (1) CA2722016C (es)
CL (1) CL2009000906A1 (es)
CO (1) CO6300844A2 (es)
CR (1) CR11684A (es)
DE (1) DE102008020113A1 (es)
DO (1) DOP2010000282A (es)
EC (1) ECSP10010494A (es)
ES (1) ES2535458T3 (es)
HN (1) HN2010001920A (es)
IL (1) IL208136A0 (es)
MA (1) MA32251B1 (es)
MX (1) MX2010010324A (es)
NZ (1) NZ588721A (es)
PE (1) PE20091732A1 (es)
RU (1) RU2509080C9 (es)
SV (1) SV2010003674A (es)
TW (1) TWI433846B (es)
UA (1) UA105487C2 (es)
UY (1) UY31765A (es)
WO (1) WO2009129945A1 (es)
ZA (1) ZA201006719B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
CN103052632B (zh) * 2010-08-18 2014-03-19 山东亨利医药科技有限责任公司 二氢吡唑类化合物
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
WO2012126275A1 (zh) * 2011-03-18 2012-09-27 山东亨利医药科技有限责任公司 含有螺环的二氢吡唑类化合物
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
CA2851082A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
HK1203946A1 (en) * 2011-10-17 2015-11-06 Bayer Intellectual Property Gmbh Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
CN104321318A (zh) * 2012-03-30 2015-01-28 第一三共株式会社 4-烷酰基氨基-3-吡唑啉酮衍生物
CA2872726C (en) * 2012-05-08 2020-07-07 Hans-Christian Militzer Method for the preparation of triazole compounds
JOP20190080A1 (ar) * 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3697776B1 (en) * 2017-10-17 2023-04-19 Palau Pharma, S.L.U. Synthesis of 4-aminopyrimidine compounds
CN109694380B (zh) * 2017-10-23 2022-09-27 中国医药研究开发中心有限公司 二氢吡唑啉酮类化合物及其制备方法和医药用途
CN111825690B (zh) * 2019-04-17 2022-09-27 中国医药研究开发中心有限公司 一种phd抑制剂的新晶型及其制备方法
CN111825689B (zh) * 2019-04-17 2023-05-05 中国医药研究开发中心有限公司 一种二氢吡唑啉酮类化合物的晶型及其制备方法
US20230067910A1 (en) * 2019-11-19 2023-03-02 Modag Gmbh Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075003A (en) * 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) * 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) * 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) * 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
AU2002359714B2 (en) 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7652033B2 (en) * 2003-03-27 2010-01-26 Emory University HIF-1 inhibitors
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004236690A1 (en) * 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
EP1646382A4 (en) 2003-06-30 2010-07-21 Hif Bio Inc COMPOUNDS, COMPOSITIONS AND METHODS
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
EP1768687A2 (en) * 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
WO2006101903A1 (en) 2005-03-16 2006-09-28 Aventis Pharmaceuticals Inc. Dipyrazoles as central nervous system agents
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
JP5237712B2 (ja) * 2008-07-25 2013-07-17 公立大学法人 滋賀県立大学 静電紡糸装置

Also Published As

Publication number Publication date
IL208136A0 (en) 2010-12-30
HK1156306A1 (en) 2012-06-08
US20120035151A1 (en) 2012-02-09
CN102015685A (zh) 2011-04-13
RU2509080C2 (ru) 2014-03-10
CO6300844A2 (es) 2011-07-21
US20140038938A1 (en) 2014-02-06
UY31765A (es) 2009-12-14
TWI433846B (zh) 2014-04-11
CA2722016C (en) 2016-09-20
HN2010001920A (es) 2013-10-22
MX2010010324A (es) 2010-11-05
ECSP10010494A (es) 2010-10-30
AR071376A1 (es) 2010-06-16
ZA201006719B (en) 2011-11-30
NZ588721A (en) 2012-10-26
DE102008020113A1 (de) 2009-10-29
US8067407B2 (en) 2011-11-29
RU2509080C9 (ru) 2014-08-20
WO2009129945A1 (de) 2009-10-29
CA2722016A1 (en) 2009-10-29
BRPI0911594A2 (pt) 2017-10-10
EP2265602A1 (de) 2010-12-29
JP2011518794A (ja) 2011-06-30
US20090269420A1 (en) 2009-10-29
AU2009240311A1 (en) 2009-10-29
KR20100135838A (ko) 2010-12-27
UA105487C2 (uk) 2014-05-26
CL2009000906A1 (es) 2010-04-09
MA32251B1 (fr) 2011-04-01
RU2010147404A (ru) 2012-05-27
AU2009240311B2 (en) 2014-02-27
JP5579165B2 (ja) 2014-08-27
TW201006825A (en) 2010-02-16
DOP2010000282A (es) 2010-11-15
ES2535458T3 (es) 2015-05-11
CN102015685B (zh) 2014-10-15
SV2010003674A (es) 2011-01-14
EP2265602B1 (de) 2015-04-08
US8580778B2 (en) 2013-11-12
CR11684A (es) 2011-03-24

Similar Documents

Publication Publication Date Title
PE20091732A1 (es) Dihidropirazolonas sustituidas y su uso
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
UY29457A1 (es) Compuestos novedosos de derivados de aminosulfonilo
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
PE20081372A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[4-(7-ETIL-5H-PIRROLO[2,3-b]PIRAZIN-6-IL)-FENIL]-PROPAN-2-OL COMO INHIBIDOR DE QUINASA
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
BR122013025375B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20140244A1 (es) Composicion farmaceutica, metodos de tratamiento y usos de la misma
CY1110108T1 (el) Παραγωγα ισοκινολινης ως αναστολεις της rho-κινασης
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
AR059249A1 (es) Compuesto amina trisustituido
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
ECSP077372A (es) Antagonistas del receptor de trombina
SV2010003723A (es) Derivados de piperidina 3,4-sustituida como inhibidores de renina
PE20081596A1 (es) Derivados fluorinados de deferiprona

Legal Events

Date Code Title Description
FG Grant, registration
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed